{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-217945","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.313683+00:00","generated_at":"2026-06-24T01:14:38.086344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veru Q3 net loss $22.2M on 46% revenue decline; sabizabulin EUA under FDA, UK, EMA review","bullets":["Net loss of $22.2M ($0.28 per share) vs $2.7M loss a year ago; revenue $9.6M vs $17.7M.","Sabizabulin EUA submitted to FDA June 2022; UK MHRA granted expedited review; EMA Emergency Task Force reviewing for EU emergency use.","Phase 3 COVID-19 trial showed 55.2% relative reduction in deaths; results published in NEJM Evidence.","ENTADFI (tadalafil/finasteride) commercially launched for BPH; FC2 prescription sales down 50% due to telemedicine customer issues.","Cash and equivalents $100.6M as of June 30, 2022, down from $122.4M at Sep 30, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-217945","json":"https://secwatch.observer/filing/0001193125-22-217945.json","markdown":"https://secwatch.observer/filing/0001193125-22-217945.md","text":"https://secwatch.observer/filing/0001193125-22-217945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/0001193125-22-217945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/d393861d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:14:38.086344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}